๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials in this register

19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
NCT05450835Gastric Cancer
Nanfang Hospital, Southern Medical University
Not applicable
344
Quanzhou, Guangzhou, Shantou, Ganzhou, Changsha, Hengyang, Changchun, Shenyang
2022-09-01
Recruiting
Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy
NCT06279247Narcolepsy
Qilu Hospital of Shandong University
Observational
60
Jinan
2022-09-01
Recruiting
Olverembatinib for FGFR1-rearranged Neoplasms
NCT05521204Myeloproliferative Neoplasm, Acute Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
20
Suzhou
2022-09-01
Recruiting
Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer
NCT05511623Cervical Cancer
First Affiliated Hospital of Guangxi Medical University
Phase 2
112
Nanning
2022-09-01
Not yet open
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
NCT05524974Locally Advanced Gastric Cancer
Fujian Medical University
Phase 2
203
Fuzhou
2022-09-01
Recruiting
Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma
NCT05563922Rectal Cancer
Shanghai Zhongshan Hospital
Phase 2
56
Shanghai
2022-09-01
Recruiting
A Study on the Correlation Between Cotinine Levels and Aneurysm Wall Enhancement on HRMRI.
NCT06447714Cotinine Levels, Arterial Aneurysm Wall Enhancement on HRMRI
Zhujiang Hospital
Observational
450
Guangzhou
2022-09-01
Active, closed
Multimodal Prehabilitation To Improve The Clinical Outcomes Of Frail Elderly Patients With Gastric Cancer
NCT05352802Stomach Neoplasms, Frail Elderly
The Affiliated Hospital of Qingdao University
Not applicable
368
Qingdao
2022-09-01
Recruiting
Dual-port Trans-subclavian Thyroid Endoscopic Surgery
NCT06398795Thyroid Neoplasms, Endoscopic Surgery
First Affiliated Hospital of Wenzhou Medical University
Not applicable
300
Wenzhou
2022-09-01
Recruiting
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
NCT05514327Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy, Bridging Therapy
Peking Union Medical College Hospital
Not applicable
20
Beijing
2022-09-01
Recruiting
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
NCT05495035Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
19
Hefei, Jinan, Tianjin, Shanghai
2022-09-01
Not yet open
Non-invasive Transcranial Focused Low-intensity Ultrasound Stimulation in Patients With Mild Lewy Body Dementia
NCT05499429Lewy Body Dementia
Xuanwu Hospital, Beijing
Not applicable
20
Beijing
2022-09
Not yet open
Long Term Prospective Study of Tai Chi Intervention to Delay the Progression of Subjective Cognitive Impairment
NCT05485025Subjective Cognitive Impairment
Ruijin Hospital
Not applicable
134
Shanghai
2022-09
Active, closed
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
NCT05460767Solid Tumors or Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
504
Hangzhou
2022-08-31
Recruiting
Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU
NCT05500118Leiomyoma, Uterine, High-Intensity Focused Ultrasound Ablation, Patients Decision Aids
Shenzhen Maternity & Child Healthcare Hospital
Observational
120
Shenzhen
2022-08-31
Active, closed
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
NCT05459844Neuroendocrine Tumors
Sinotau Pharmaceutical Group
Phase 3
196
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun
2022-08-31
Not yet open
To Evaluate the Efficacy and Safety of the Transfemoral Mitral Valve Repair System in the Treatment of Patients With Moderately Severe and Severe Functional Mitral Regurgitation(FMR) Who Remained Clinically Symptomatic After Guideline-directed Medical Treatment
NCT05508438Mitral Valve Insufficiency
Pan Xiangbin
Not applicable
140
Beijing
2022-08-30
Active, closed
Selective Neck Dissection Under Multimodal Assessment for N3 Nasopharyngeal Carcinoma After Radiotherapy
NCT07636499Nasopharyngeal Cancinoma (NPC)
Guiquan Zhu
Phase 1
50
Chengdu
2022-08-30
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals
Phase 4
347
Chongqing, Guangzhou, Zhengzhou, Wuhan, Changchun, Xian, Chengdu, Beijing
2022-08-30
Recruiting
Early Warning and Classification Model for Acute Non-traumatic Chest Pain
NCT06196307Chest Pain
Xiao-nan He
Observational
10,000
Beijing
2022-08-30
Active, closed
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients (TOPICS-THYROID)
NCT05541380Thyroid Cancer
National Health Research Institutes, Taiwan
Observational
300
2022-08-29
Recruiting
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
NCT05626400T-cell Acute Lymphoblastic Leukemia/Lymphoma
Hebei Senlang Biotechnology Inc., Ltd.
Not applicable
100
Beijingcun
2022-08-29
Recruiting
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
NCT05341557Advanced Solid Tumor, Lymphoma, NSCLC, HCC
Betta Pharmaceuticals Co., Ltd.
Phase 1
110
Chaoyang, Cangzhou, Tianjin
2022-08-29
Recruiting
China HeadAche DIsorders RegiStry
NCT05334927Headache Disorders, Primary, Migraine, New Daily Persistent Headache, Medication Overuse Headache
Beijing Tiantan Hospital
Observational
10,000
Anqing, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Shenzhen
2022-08-29
Active, closed
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
NCT05518045Advanced Solid Tumor
LaNova Medicines Limited
Phase 1/2
392
Beijing
2022-08-26
Recruiting
Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma
NCT06163729Gastroesophageal Junction Adenocarcinoma (Siewert II-III)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
68
Beijing
2022-08-25
Recruiting
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
NCT05417321Advanced Solid Tumor, NSCLC
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2
80
Jinan
2022-08-25
Recruiting
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
NCT05240950Colorectal Cancer, Metastatic Liver Cancer
Changhai Hospital
Phase 1
18
Shanghai
2022-08-25
Recruiting
The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma
NCT05774275High-Risk Localized Soft Tissue Sarcoma
Fudan University
Phase 1/2
52
Shanghai
2022-08-25
Recruiting
Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction
NCT05512286Breast Cancer
Fudan University
Not applicable
80
Nanning, Zhengzhou, Changsha, Shanghai, Kunming, Hangzhou
2022-08-25
Recruiting
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
NCT05473624Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
NCT05477849Advanced Malignant Solid Tumor
Shanghai Virogin Biotech Co., Ltd.
Phase 1
30
Hangzhou
2022-08-23
Recruiting
A Prospective Observation Registry Study on the Alimentary Reconstruction After Radical Proximal Gastrectomy
NCT05539105Proximal Gastric Adenocarcinoma, Reconstruction
Shanghai Zhongshan Hospital
Observational
600
Shanghai
2022-08-22
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
Sanofi
Phase 2/3
1,856
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang
2022-08-22
Recruiting
The Cohort Study of Pediatric Cataract
NCT05472844Pediatric Cataract
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
5,000
Guangzhou
2022-08-22
Recruiting
The Registry Study of Genetic Alterations of Melanoma in Taiwan
NCT06952400Primary Melanoma of the Extremity
National Health Research Institutes, Taiwan
Observational
250
2022-08-22
Recruiting
A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
NCT05409482Hepatocellular Carcinoma
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Observational
300
Fuzhou
2022-08-20
Active, closed
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
NCT05413018Leukemia, Myeloid, Acute
Bristol-Myers Squibb
Phase 2
34
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Shijiazhuang, Xuzhou, Shenyang
2022-08-19
Recruiting
KSH01-TCRT Solid Tumors
NCT05539833TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors
TCRx Therapeutics Co.Ltd
Phase EARLY_PHASE1
50
Nanning
2022-08-19
Recruiting
Utidelone Combined With Bevacizumab in the Treatment of โ‰ฅ 2 Lines of HER-2 Negative Advanced Breast Cancer
NCT05398861HER-2 Negative Breast Cancer
Henan Cancer Hospital
Phase 2
79
Zhengzhou
2022-08-19
Active, closed
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
NCT05507632Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2
48
Guangzhou
2022-08-18
Active, closed
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT05424822Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC
Phase 1
167
Chongqing, Guangzhou, Tianjin, Wuhan
2022-08-18
Active, closed
A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT05314010Neuromyelitis Optica Spectrum Disorder
Beijing Mabworks Biotech Co., Ltd.
Phase 3
102
Beijing
2022-08-18
Recruiting
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
NCT05276726Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc.
Phase 1/2
104
Beijing, Chongqing, Xiamen, Shenzhen, Nanning, Shijiazhuang, Harbin, Zhengzhou
2022-08-17
Active, closed
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530Locally Advanced or Metastatic Urothelial Carcinoma
EMD Serono Research & Development Institute, Inc.
Phase 2
256
2022-08-17
Recruiting
3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension
NCT05475015Cirrhosis, Liver, Portal Hypertension, Advanced Chronic Liver Disease
Shengjing Hospital
Observational
150
Shenyang
2022-08-16
Recruiting
68Ga-RM26-RGD PET/CT Imaging in the GRPR and ฮฑvฮฒ3 Positive Tumor Patients
NCT05549024Breast Cancer, Prostate Cancer, Brain Tumor, PET/CT Imaging
Peking Union Medical College Hospital
Phase EARLY_PHASE1
90
Beijing
2022-08-16
Recruiting
3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
NCT06205992Cirrhosis, Liver Portal Hypertension
Shengjing Hospital
Observational
100
Shenyang
2022-08-16
Recruiting
Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
NCT07327216Nasopharyngeal Carcinoma (NPC)
Affiliated Hospital of Guangdong Medical University
Phase 3
180
Zhanjiang
2022-08-15
Recruiting
Latent Infection Freshmen Tracking for Tuberculosis
NCT07811518Latent Tuberculosis Infection (LTBI), Tuberculosis (TB)
Affiliated Hospital of Nantong University
Phase 4
3,000
Nantong, Meishan
2022-08-15
Recruiting
Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi
NCT05551208Ovarian Cancer
Chongqing University Cancer Hospital
Phase 2
42
Chongqing
2022-08-15
Recruiting
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
NCT05484908Immune-Mediated Hepatitis, Liver Failure, Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
60
Guangzhou
2022-08-12
Active, closed
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
NCT05651178Central Nervous System Lymphoma
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1
10
Nanchang
2022-08-12
Recruiting
International Study of Cerebral Oxygenation and Electrical Activity During Major Neonatal Surgery
NCT05673499Congenital Disorders, Cerebral Desaturation, Neonatal Surgery
Children's Hospital of Philadelphia
Observational
900
Guangzhou, Shanghai, Shenyang, Sichuan
2022-08-12
Active, closed
PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas
NCT05473923Recurrent High Grade Glioma
Beijing Tiantan Hospital
Phase EARLY_PHASE1
30
Beijing
2022-08-12
Recruiting
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
NCT05506410Newly Diagnosed Mantle Cell Lymphoma
Zhengzhou University
Observational
100
Zhengzhou
2022-08-12
Recruiting
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma๏ผˆKeyplus-001๏ผ‰
NCT05357651Solid Tumor, Lymphoma
L & L Bio Co., Ltd., Ningbo, China
Phase 1
100
Shanghai
2022-08-12
Recruiting
68Ga-N188 PET/CT Imaging in Malignancy
NCT05593107Neoplasms
Peking University First Hospital
Not applicable
203
Beijing
2022-08-12
Recruiting
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT05470348Breast Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
36
Guangzhou, Shanghai
2022-08-11
Active, closed
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
NCT05192486Diffuse Large B-cell Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
12
Shenzhen, Baoding, Luoyang, Shanghai
2022-08-10
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
240
Nanning, Wuhan, Shenyang, Yinchuan, Beijing, Shenzhen
2022-08-10
Active, closed
A Research Study to Compare Somapacitan Once a Week With Norditropinยฎ Once a Day in Children Who Need Help to Grow
NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS
Novo Nordisk A/S
Phase 3
412
Beijing, Guangzhou, Liuzhou, Sanya, Zhengzhou, Wuhan, Changsha, Changchun
2022-08-10
Recruiting
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
NCT05461768Breast Cancer, Locally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
348
Fuzhou, Dongguan, Guangdong, Zhengzhou, Wuhan, Jinan, Hangzhou
2022-08-09
Active, closed
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
NCT05320692Hepatocellular Carcinoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
423
Shanghai
2022-08-09
Recruiting
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
NCT05299424Multiple Myeloma
Keymed Biosciences Co.Ltd
Phase 1/2
48
Beijing
2022-08-09
Recruiting
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067
NCT05306132Advanced Solid Tumor
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1
150
Zhengzhou, Changsha, Shanghai
2022-08-08
Recruiting
Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer
NCT05466786Breast Cancer, HER2-low Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
255
Guangzhou
2022-08-07
Not yet open
Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
NCT05484024Rectal Neoplasms Malignant, Radiotherapy
Chinese Academy of Medical Sciences
Phase 2/3
588
Beijing, Shenzhen
2022-08-06
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC
Phase 3
418
Beijing, Changchun, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2022-08-05
Recruiting
Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation
NCT06809699Hematologic Diseases
He Huang
Phase 1
29
Hangzhou
2022-08-04
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
Novartis Pharmaceuticals
Phase 3
506
Hefei, Chongqing, Nanjing, Nanchang, Pingxiang, Changchun, Taiyuan, Chengdu
2022-08-04
Recruiting
The Beijing Angle Closure Progression Study
NCT05563623Angle-Closure Glaucoma
Peking University People's Hospital
Observational
825
Beijing
2022-08-04
Active, closed
A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
NCT05424835HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
381
Guangzhou
2022-08-04
Recruiting
The Roles of Human Microbiome and Vitamin D in the Development of Childhood Allergic Diseases
NCT05670262Pediatric
China Medical University Hospital
Observational
6,000
2022-08-04
Recruiting
Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation
NCT06809712Hematologic Disease
He Huang
Phase 1
29
Hangzhou
2022-08-04
Recruiting
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
NCT05410145KRAS P.G12C
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
Hefei, Beijing, Guangzhou, Hangzhou, Harbin, Wuhan, Changsha, Zhengzhou
2022-08-03
Recruiting
Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors
NCT05468970Bone and Soft Tissue Tumors, Clinical Features
Henan Cancer Hospital
Observational
6,000
Zhengzhou
2022-08-03
Active, closed
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Phase 1
276
Beijing, Guangzhou, Wuhan
2022-08-03
Active, closed
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
341
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2022-08-03
Recruiting
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
NCT05507411Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Phase 2
100
Hanzhou, Ningbo
2022-08-03
Recruiting
Chinese Colorectal Cancer Database
NCT05434026Colonic Cancer, Rectal Cancer, Prospective Studies
Beijing Friendship Hospital
Observational
200,000
Beijing
2022-08-03
Recruiting
A Exploratory Study of Vฮณ2Vฮด2 T Lymphocyte-based Immunotherapy for MDR-TB
NCT05493267MDR-TB, Immunotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
30
Shanghai
2022-08-03
Recruiting
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
NCT06732531Bladder Cancer, Non Muscle Invasive
Zhuhai Beihai Biotech Co., Ltd
Phase 1/2
48
Beijing, Xiamen, Changsha, Shenyang, Shanghai, Tianjin
2022-08-03
Recruiting
Health-Related Quality of Life and Emotions in Patients with Thyroid Nodules
NCT06610604Thyroid Nodule
Ming-an Yu
Observational
500
Beijing
2022-08-01
Recruiting
Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
NCT05600660Primary Central Nervous System Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
28
Hanzhou
2022-08-01
Recruiting
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT05495152Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
Phase 3
219
Zhengzhou
2022-08-01
Active, closed
Pre-operative Surgical Difficulty Stratification Using Predicted Tumor Perfusion and Consistency
NCT06664190Pituitary Adenoma
Huashan Hospital
Observational
200
Shanghai
2022-08-01
Recruiting
Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
NCT06087068Thyroid Cancer, Surgery, Recurrence
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
140
Beijing
2022-08-01
Recruiting
Screening and Molecular Diagnosis-based Individualized Precision Management of Monogenic Diabetes
NCT06746610Monogenic Diabetes
Tianjin Medical University General Hospital
Not applicable
2,000
Tianjin
2022-08-01
Recruiting
Short-course Radiotherapy (5ร—6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer
NCT03466424Radiation Oncology, Rectal Cancer
Fujian Medical University Union Hospital
Observational
9
Fuzhou
2022-08-01
Recruiting
Effect of GH on the Blastocyst Euploid Rate in AMA Patients
NCT05447208Preimplantation Genetic Testing, Growth Hormone, Age, Parental
ShangHai Ji Ai Genetics & IVF Institute
Phase 3
400
Shanghai
2022-08-01
Recruiting
Lung Health of Early COPD: A Multi-center Cohort Study
NCT05466396COPD
Ting YANG
Observational
1,550
Beijing, Zunyi
2022-08-01
Recruiting
The Combination of Radiotherapy๏ผŒSurufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma
NCT05839275High-Risk Localized Soft Tissue Sarcoma
Fudan University
Phase 1/2
52
Shanghai
2022-08-01
Recruiting
TreAtments and outComes in paTients With prImary CutAneous Lymphoma
NCT05518851Primary Cutaneous Lymphoma
Peking University First Hospital
Observational
3,000
Beijing, Guandong, Nanjing, Jinan
2022-08-01
Recruiting
Radiotherapy Combined With Endostatin and Capecitabine for NPC
NCT05514275Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2
41
Hangzhou, Jiaxing, Jinhua, Lishui, Ningbo, Quzhou
2022-08-01
Active, closed
Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis
NCT07071246Treatment
Tang-Du Hospital
Not applicable
30
Xi'an
2022-08-01
Recruiting
Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism
NCT07328230Idiopathic Hyperaldosteronism, Hyperaldosteronism
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
172
Beijing, Nanchang, Chengdu
2022-08-01
Recruiting
Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
NCT05457049Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Observational
180
Foshan, Guangzhou, Shantou, Zhongshan
2022-08-01
Active, closed
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
NCT05468138MSI-H, PD-1 Immunotherapy, Gastric Cancer, Adjuvant Therapy
Fudan University
Phase 2
94
Shanghai
2022-08-01
Recruiting
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
NCT05888909Diabetic Nephropathy Type 2, Diabetic Kidney Disease, Type 2 Diabetes
Chinese PLA General Hospital
Observational
2,000
Beijing
2022-08-01
Rows per page Showing 16301–16400 of 19052
Previous 162 163 164 165 166 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china?page=164

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in China?

11,786 of the 19,052 studies in this register are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3,920 have not yet opened recruitment, 2,668 are active but closed to new participants, and 678 are enrolling by invitation only. Eligibility for any study is decided by its study team.

→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.